1 citations
,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
November 2023 in “PubMed” Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
3 citations
,
March 2020 in “Dermatology Research and Practice” Tracnil™, a mix of myo-inositol, folic acid, and vitamin D3, safely reduced acne, improved excessive hair growth, and fixed irregular periods in overweight women with PCOS.
61 citations
,
March 1990 in “Clinical pharmacology and therapeutics/Clinical pharmacology & therapeutics” Albendazole treatment for echinococcosis can cause serious side effects and requires close monitoring.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
2 citations
,
March 1964 in “Archives of Dermatology” Different doses of triamcinolone injections work equally well for skin conditions.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” May 2026 in “Bioorganic Chemistry”
14 citations
,
January 2020 in “International Journal of Biological Sciences” Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
8 citations
,
August 2023 in “Lasers in Surgery and Medicine” Concurrent laser and isotretinoin treatment improves acne scars more than delayed treatment.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
2 citations
,
January 2016 in “İzmir Dr.Behçet Uz çocuk hastanesi dergisi” A child's scalp infection was caused by a fungus not previously known to do so, but it was successfully treated.
1 citations
,
August 2024 in “Journal of Cosmetic and Laser Therapy” Intralesional vitamin D3 is an effective and safe treatment for patchy alopecia areata with fewer side effects.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
19 citations
,
December 2019 in “Journal of the American Academy of Dermatology” 5 mg/mL of triamcinolone acetonide is most effective for hair regrowth with fewer side effects.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
18 citations
,
December 2015 in “PubMed” Intralesional triamcinolone is more effective than topical betamethasone for treating localized alopecia areata.
May 2026 in “Journal of Asia Pacific Aesthetic Sciences” Low-dose intralesional corticosteroid treatment led to rapid hair regrowth in localized alopecia areata.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.